Hudson Edge Investment Partners Inc. Acquires 17,191 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Hudson Edge Investment Partners Inc. increased its stake in Bristol Myers Squibb Company by 15%, acquiring an additional 17,191 shares to own 131,574 shares overall, valued at approximately $6.09 million.
• Bristol Myers Squibb reported an EPS of $1.46 for the last quarter, surpassing the consensus estimate of $1.07, with revenues reaching $12.27 billion.
• The company announced a quarterly dividend of $0.62 per share, translating to a 5.4% dividend yield, with a payout ratio of 100%.

Hudson Edge Investment Partners Inc. increased its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 15.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 131,574 shares of the biopharmaceutical company's stock after buying an additional 17,191 shares during the period. Hudson Edge Investment Partners Inc.'s holdings in Bristol Myers Squibb were worth $6,091,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of BMY. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Bristol Myers Squibb during the 1st quarter worth $31,000. Accent Capital Management LLC bought a new position in Bristol Myers Squibb in the first quarter worth about $33,000. CBIZ Investment Advisory Services LLC lifted its position in shares of Bristol Myers Squibb by 66.0% during the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 231 shares during the last quarter. GKV Capital Management Co. Inc. bought a new stake in shares of Bristol Myers Squibb in the 1st quarter valued at about $36,000. Finally, EQ Wealth Advisors LLC purchased a new position in shares of Bristol Myers Squibb in the 1st quarter worth approximately $37,000. Institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $45.75 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.96 and a twelve month high of $63.33. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The company has a market cap of $93.12 billion, a PE ratio of 18.45, a price-to-earnings-growth ratio of 2.43 and a beta of 0.33. The company's 50 day moving average is $46.42 and its 200 day moving average is $48.76.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.07 by $0.39. The business had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business's revenue for the quarter was up .6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be issued a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.4%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb's payout ratio is 100.00%.

Insider Activity at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the firm's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the sale, the executive vice president directly owned 167,379 shares of the company's stock, valued at $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages have weighed in on BMY. Daiwa America downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Citigroup lowered their price objective on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating for the company in a research report on Friday, August 1st. Wall Street Zen downgraded Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. Morgan Stanley reiterated a "hold" rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Finally, Daiwa Capital Markets lowered Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price target on the stock. in a research note on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $56.38.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.